Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead of a fight for market share with companies including Bristol Myers Squibb and Johnson & Johnson.
In December, Takeda reported two phase 3 trials of its TYK2 inhibitor, zasocitinib, in adults with moderate to severe plaque psoriasis met their primary endpoints. The Japanese drugmaker later teased bits of the data, revealing that more than 50% of patients had a 90% improvement on the PASI scale and that about 30% of participants had clear skin, but it kept the full dataset under wraps.
Saturday, Takeda used the 2026 American Academy of Dermatology (AAD) Annual Meeting to provide a closer look at the results. Zasocitinib’s PASI 90 rates were 61.3% and 51.9% at Week 16 of the two trials, versus 5% and 4% for placebo and 16.8% and 15.9% for apremilast. Amgen sells apremilast as Otezla.
Takeda reported rates of PASI 100, which indicates clear skin, of 33.4% and 25.2% in people treated with zasocitinib at Week 16. The figures for placebo were 0.7% and 1.1%. On apremilast, 2.9% and 4.3% of patients met the PASI 100 criteria. Zasocitinib beat the controls by similar margins on the sPGA psoriasis symptom scale, providing strong evidence that the molecule is more effective than placebo and Otezla.
If approved, zasocitinib will compete with more efficacious therapies than placebo and Otezla. BMS sells a TYK2 inhibitor, Sotyktu, and Alumis has positive phase 3 data on a molecule that hits the target. J&J and Protagonist Therapeutics recently won FDA approval for an IL-23 receptor antagonist, Icotyde, that beat BMS’ Sotyktu in a phase 3 trial.
With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its phase 3 program.
J&J and Alumis look to pose more of a threat to Takeda. The FDA approved (PDF) Icotyde based on two phase 3 trials in adults that reported PASI 90 rates of up to 55% and PASI 100 rates of up to 32% at Week 16. Alumis, which is also presenting data at AAD Saturday, said in its topline release that, averaged across its two trials, about 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24.
Andrew Plump, M.D., Ph.D., president of R&D at Takeda, discussed how zasocitinib compares to Alumis’ envudeucitinib at a TD Cowen event in early March. Lacking Alumis’ full data, Plump said it is hard to say how the molecules shape up, but he named dosing as an area Takeda has “considerable differentiation.” Zasocitinib is taken once a day, while envudeucitinib is taken twice a day.
J&J’s Icotyde is taken once a day but must be swallowed on an empty stomach. Patients need to take the drug with water when they wake up and wait 30 minutes before eating because of the molecule’s food effect. Alumis saw no clinically significant food effect in a study of envudeucitinib. Plump said there is no food effect with zasocitinib, something he predicted will be “quite important for this class.”
A lot is resting on how the molecules’ strengths and weaknesses translate into market share. Takeda has forecast peak potential zasocitinib revenue of $3 billion to $6 billion in psoriasis and psoriatic arthritis, reflecting a belief that the candidate is as good or better than any other oral drug that is approved or coming to market in the near future.
Takeda is on track to seek regulatory approvals in its 2026 financial year, which starts in April.
Facts Only
Takeda acquired zasocitinib, a TYK2 inhibitor, for $4 billion.
Phase 3 trials for zasocitinib in moderate to severe plaque psoriasis met primary endpoints in December 2025.
Detailed results were presented at the 2026 American Academy of Dermatology Annual Meeting.
Zasocitinib achieved PASI 90 rates of 61.3% and 51.9% at Week 16 in two trials.
Placebo PASI 90 rates were 5% and 4%; apremilast (Otezla) rates were 16.8% and 15.9%.
PASI 100 (clear skin) rates for zasocitinib were 33.4% and 25.2% at Week 16.
Placebo PASI 100 rates were 0.7% and 1.1%; apremilast rates were 2.9% and 4.3%.
Bristol Myers Squibb’s Sotyktu (TYK2 inhibitor) reported PASI 90 rates of 32-42% and PASI 100 rates of 10-14%.
Johnson & Johnson’s Icotyde (IL-23 receptor antagonist) achieved PASI 90 rates up to 55% and PASI 100 up to 32%.
Alumis’ envudeucitinib (TYK2 inhibitor) reported average PASI 90 rates of 65% and PASI 100 rates over 40% at Week 24.
Zasocitinib is dosed once daily with no food restrictions.
Takeda projects peak zasocitinib revenue of $3 billion to $6 billion.
Regulatory submissions for zasocitinib are planned for Takeda’s 2026 financial year.
Executive Summary
Takeda has unveiled detailed phase 3 trial results for zasocitinib, its TYK2 inhibitor for moderate to severe plaque psoriasis, at the 2026 American Academy of Dermatology Annual Meeting. The data show zasocitinib achieved PASI 90 response rates of 61.3% and 51.9% at Week 16, significantly outperforming placebo (5% and 4%) and apremilast (16.8% and 15.9%). Clear skin (PASI 100) was achieved by 33.4% and 25.2% of zasocitinib-treated patients, compared to near-zero rates in placebo and low single digits for apremilast. Takeda acquired zasocitinib in a $4 billion deal and projects peak revenues of $3 billion to $6 billion, positioning it as a leading oral therapy in psoriasis and psoriatic arthritis.
The competitive landscape includes Bristol Myers Squibb’s TYK2 inhibitor Sotyktu, which reported lower PASI 90 (32-42%) and PASI 100 (10-14%) rates, and Johnson & Johnson’s newly approved IL-23 receptor antagonist Icotyde, which demonstrated PASI 90 rates up to 55% and PASI 100 up to 32%. Alumis’ envudeucitinib, another TYK2 inhibitor, showed higher Week 24 PASI 90 (65%) and PASI 100 (40%) rates but requires twice-daily dosing, while zasocitinib is once-daily with no food restrictions. Takeda plans regulatory submissions in its 2026 financial year, emphasizing zasocitinib’s convenience and efficacy as key differentiators.
Full Take
**Steelman:** Takeda’s zasocitinib data presents a compelling case for a highly effective oral psoriasis treatment, with superior efficacy to placebo and apremilast, and potential advantages over competitors like Sotyktu in both dosing convenience and response rates. The absence of food restrictions and once-daily dosing could enhance patient adherence, a critical factor in chronic disease management. Takeda’s revenue projections reflect confidence in zasocitinib’s market potential, backed by robust phase 3 data.
**Pattern Scan:** The narrative leans heavily on comparative efficacy claims, which, while data-driven, risk oversimplifying cross-trial comparisons—a known limitation in clinical research. The emphasis on zasocitinib’s dosing advantages over competitors (e.g., Alumis’ twice-daily envudeucitinib) could be framed as a subtle appeal to convenience as a proxy for superiority, though the data supports this distinction. No overt manipulation patterns are detected, but the framing of "market share fights" and revenue projections may subtly prime readers to view the drug’s success as inevitable, which could downplay uncertainties in regulatory approval or real-world performance.
**Root Cause:** The underlying paradigm here is the pharmaceutical industry’s race to dominate lucrative autoimmune markets through incremental innovation—tying efficacy, convenience, and pricing to competitive positioning. The unstated assumption is that higher PASI response rates and dosing simplicity will directly translate to market dominance, ignoring potential variables like pricing, insurance coverage, or long-term safety profiles.
**Implications:** For patients, zasocitinib’s profile could mean more effective, user-friendly treatment options, but the focus on market share raises questions about whether competition will drive down costs or merely shift prescribing patterns among high-priced alternatives. The second-order consequence may be a consolidation of oral psoriasis therapies around TYK2 and IL-23 inhibitors, potentially sidelining older or less profitable treatments.
**Bridge Questions:** How might long-term safety data or real-world adherence rates alter the competitive landscape? What role will pricing and insurance coverage play in determining zasocitinib’s market penetration? Could the emphasis on PASI 90/100 metrics obscure other patient-reported outcomes, like quality of life or side effect tolerance?
**Counterstrike Scan:** A coordinated influence campaign would likely amplify zasocitinib’s advantages while downplaying competitors’ strengths (e.g., Alumis’ higher Week 24 response rates) or omitting context about cross-trial variability. The actual content avoids this, presenting competitor data transparently and acknowledging dosing as a key differentiator rather than a sole determinant of success. No structural alignment with manipulative playbooks is detected.
Sentinel — Human
This article appears to be written by a human journalist.